Eli Lilly Slips, Novo Nordisk Holds Firm as Generic Weight-Loss Drugs Flood India

Eli Lilly slips, Novo Nordisk holds firm as generic weight-loss drugs flood India

Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.

Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead: report (LLY:NYSE)

Low-cost semaglutide generics are reshaping India’s obesity/GLP-1 market, cutting Lilly’s Mounjaro share and signaling patent-cliff risks—

India's Generic Copies Dent Eli Lilly's Sales

(Bloomberg) — The flood of cheap copies of Novo Nordisk A/S’ blockbuster drug semaglutide in India is already reshaping the country’s fast-growing obesity market, cutting into Eli Lilly & Co.’s early lead and offering a first real test of how Novo may fare as its patents expire worldwide.